Please ensure Javascript is enabled for purposes of website accessibility

A Beginner's Guide to Growth Stocks

By Shannon Zimmerman - Updated Nov 11, 2016 at 4:47PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Can you turn a love affair with growth into a sound investment?

Come on, admit it: Like most of us, you gravitate toward the market's highfliers. You know, the stocks with sex appeal -- and price multiples that make those of the broader market look like the proverbial chicken feed. Google (Nasdaq: GOOG), Genentech (NYSE: DNA), Bristol-Myers Squibb (NYSE: BMY), and Visa (NYSE: V), for example, all sport price-to-earnings (P/E) ratios that surpass the broader market's. Monsanto (NYSE: MON), Teva Pharmaceutical (Nasdaq: TEVA), and Biogen Idec (Nasdaq: BIIB) also look pricey compared with the market's multiple.

Why are investors willing to pay such premiums? Well, earnings-growth estimates are typically a major factor, but don't discount the aforementioned sex appeal. Not for nothing do highfliers typically garner miles of column inches in the financial press. 

How to proceed
If you find yourself besotted with racy growth stocks, your smartest move is to take a cold shower. Remember that the higher they fly, the farther they have to fall when Mr. Market takes a tumble. Just ask folks who invested in the growth-heavy Nasdaq 100 Trust (QQQQ) exchange-traded fund back in early 2000 -- right before the bottom fell out of the market. More than eight years later, those investors are still waiting to see a positive return on their investment.

The good news is that it doesn't have to be that way -- especially not these days. Large-cap stocks of the growth persuasion have been out of favor on a relative basis ever since the market experienced its pre-millennium meltdown. The upshot? Now appears to be an excellent time for investors to go growth shopping. After years of market-lagging performance, that seems to be where the market's bargains lie -- provided you know how to find them.

Three rules of thumb on that front are:

1. Follow the cash flow. Among the big boys, favor growth-oriented companies with a proven ability to generate cash and plow sufficient sums back into expanding their businesses. That's a winning combination -- particularly if they hope to meet those outsized earnings estimates.

2. Compare like with like. Seemingly above-average multiples can be misleading. A P/E of 25 looks high relative to the broader market's P/E (roughly 13), but not so much relative to, say, that of the average biotech company (roughly 59).

3. Don't go whole hog. Be sure to own growth stocks in the context of a well-diversified portfolio that includes more mild-mannered fare. That's a smart way to work toward financial freedom -- and to get your beauty rest at night.

The Foolish bottom line
With that as a backdrop, Ready-Made Millionaire -- the Fool service that aims to provide a set-and-forget investment solution -- features a compact, real-money lineup that tilts toward large-cap growth, but also provides choice exposure to small- and mid-cap stocks and value-priced foreign fare, too. Our mission: to sail past the market's average of the next three to five years, via intelligent asset allocation and ace investment selections.

RMM will reopen to new members early next year. Between now and then, we invite you to learn more about the service by clicking right here. You'll be able to snag our absolutely free 11-Minute Millionaire special report, which is designed to help you navigate up markets and down, and we'll make sure you're among the first to know when RMM's doors swing open again.

This article was originally published on April 5, 2007. It has been updated.

Shannon Zimmerman runs point on the Fool's Ready-Made Millionaire service and doesn't own any of the securities mentioned above. Google is a Motley Fool Rule Breakers recommendation. Biogen Idec is a Stock Advisor selection. The Fool has a strict disclosure policy.

None

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Alphabet Inc. Stock Quote
Alphabet Inc.
GOOGL
$119.70 (2.63%) $3.07
Visa Inc. Stock Quote
Visa Inc.
V
$212.10 (0.88%) $1.84
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
BMY
$74.86 (-0.13%) $0.10
Teva Pharmaceutical Industries Limited Stock Quote
Teva Pharmaceutical Industries Limited
TEVA
$11.20 (1.82%) $0.20
Biogen Inc. Stock Quote
Biogen Inc.
BIIB
$221.04 (1.59%) $3.45
Monsanto Company Stock Quote
Monsanto Company
MON

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
373%
 
S&P 500 Returns
122%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/10/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.